Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164788 | 0.85 | MAOA (0.40) | GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL4016620 | 0.85 | MAPT (0.45) | ALDH1A1TSHR | |
| SCHEMBL4438716 | 0.85 | GABRA1 (0.39) | GABRA1GABRB2TRPA1ALDH1A1TSHR | |
| SCHEMBL16201010 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TSHR | |
| SCHEMBL1309790 | 0.77 | ALDH1A1 (0.43) | GABRA1GABRB2TRPA1ALDH1A1TSHR | |
| SCHEMBL4063781 | 0.75 | ALOX15 (0.44) | GABRA1GABRB2TRPA1ALDH1A1TSHR | |
| SCHEMBL5013717 | 0.75 | ADORA2A (0.52) | ALDH1A1TSHR | |
| SCHEMBL2886076 | 0.74 | IDO1 (0.40) | TRPA1ALDH1A1TSHR | |
| SCHEMBL10892049 | 0.74 | ALDH1A1 (0.41) | GABRA1GABRB2TRPA1ALDH1A1TSHR | |
| SCHEMBL25194164 | 0.74 | FOLH1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | GABRA1 4623/4885GABRB2 4698/4885TRPA1 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.